<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03041987</url>
  </required_header>
  <id_info>
    <org_study_id>2011BAI10B01</org_study_id>
    <nct_id>NCT03041987</nct_id>
  </id_info>
  <brief_title>Chinese Cohort Study of Chronic Kidney Disease</brief_title>
  <acronym>C-STRIDE</acronym>
  <official_title>Chinese Cohort Study of Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dongzhimen Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Boai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Shenzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guizhou Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the Affiliated Hospital of Chengde Medical Colledge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Hebei University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the Affiliated Hospital of Hubei Traditional Chinese Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chifeng Second Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of BaoTou Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qianfoshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Hospital of Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Minhang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Second Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the First Affiliated Hospital of the Medical College of Shihezi University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Kunming Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yuxi City People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the Second Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to explore underlying mechanisms of chronic kidney disease progression and
      its association with adverse consequences. It will enroll approximately 5000 pre-dialysis
      chronic kidney disease patients aged between 18 and 74 years in mainland China and follow-up
      for at least 5 years. Questionnaires, anthropometric measures, laboratory tests, and
      biomaterials will be collected at baseline and annually. The principal clinical outcomes of
      the study consist of renal disease events, cardiovascular events, and death.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multicenter prospective cohort study, aimed to explore underlying mechanisms
      of chronic kidney disease progression and its association with adverse consequences. The
      study will establish a baseline cohort of 5000 Chinese pre-dialysis chronic kidney disease
      patients, who will be followed up until death or dropout or starting renal replacement
      therapy. The follow-up will be conducted for at least 5 years. Their clinical information and
      biomaterials will be collected at baseline and then annually during follow-up.

      The baseline visit includes the following items: detailed demographics; socioeconomic and
      health care services information; medical and family history; medication history; and
      questionnaires concerning quality of life, health behaviors, depressive and anxiety symptoms,
      cognitive function, and physical activity. Anthropometric measures (height, weight, waist
      circumference, hip circumference, resting blood pressure, heart rate, grip strength, and
      15-feet measured walk) will also be collected. The laboratory parameters of chemistry test,
      intact parathyroid hormone, 24-hour urine electrolytes, protein creatinine ratio, and albumin
      creatinine ratio should also be collected for each participant and measured in the central
      laboratory. After the baseline visit, participants will return annually for follow-up visits
      and evaluation. The evaluating items of follow-up visits are similar to the baseline visit,
      and sample collection.

      The principal clinical outcomes of the study can be broadly categorized as renal disease
      events, cardiovascular events, and death. Renal disease events include the incident end stage
      renal disease or significant loss of renal function.Cardiovascular events include acute
      myocardial infarction, unstable angina, hospitalization for congestive heart failure,
      incident serious cardiac arrhythmia, cerebrovascular events, and peripheral vascular
      diseases. Death is further clarified as cardiac, cerebrovascular, renal, others, or unknown.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2012</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>End stage renal disease or significant loss of renal function</measure>
    <time_frame>from date of baseline examination until the date of first documented end stage renal disease or significant loss of renal function or date of death from any cause, whichever came first, up to 60 months</time_frame>
    <description>start of chronic dialysis or renal transplantation or irreversible development of glomerular filtration rate &lt;15 ml/minute per 1.73m(2) or halving of estimated glomerular filtration rate or doubling of serum creatinine compared with the value of study entry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>from date of baseline examination until the date of first documented cardiovascular events or date of death from any cause, whichever came first, up to 60 months</time_frame>
    <description>acute myocardial infarction, unstable angina, hospitalization for congestive heart failure, incident serious cardiac arrhythmia (resuscitated cardiac arrest, ventricular fibrillation, sustained ventricular tachycardia, paroxysmal ventricular tachycardia, an initial episode of atrial fibrillation or flutter, severe bradycardia or heart block), cerebrovascular events (intraparenchymal hemorrhage, subarachnoid hemorrhage, cerebral infarction, cardioembolic cerebral infarction, etc.), and peripheral vascular diseases.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>from date of baseline examination until the date of death from any cause, up to 60 months</time_frame>
    <description>death from any cause</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>Chronic Kidney Disease</arm_group_label>
    <description>Specified estimated glomerular filtration rate (eGFR) range according to different CKD etiologies. For glomerular nephrology patients, the eGFR should be ≥15 ml/minute per 1.73m(2). For diabetic nephrology patients, the defining eligibility was 15 ml/minute per 1.73m(2)≤eGFR &lt;60 ml/minute per 1.73m(2) or eGFR≥ 60 ml/minute per 1.73m(2) with &quot;nephrotic range&quot; proteinuria, which is defined as 24-hour urinary protein ≥3.5 g or urinary albumin creatinine ratio ≥2 000 mg/g or corresponding values of urine dipstick test or urinary protein creatinine ratio. For non-glomerular nephrology and non-diabetic nephrology patients, 15 ml/minute per 1.73m(2) ≤eGFR&lt;60 ml/minute per 1.73m(2) is set for enrollment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Demographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc</intervention_name>
    <arm_group_label>Chronic Kidney Disease</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples Urine samples DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study enrolled chronic kidney disease patients with a broad spectrum of renal diseases
        with various severities and phenotypes.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants should meet the following criteria of enrollment according to their etiology
        of nephrology.

          -  For glomerular nephrology patients, the estimated glomerular filtration rate (eGFR)
             should be ≥15 ml/minute per 1.73m(2).

          -  For diabetic nephrology patients, the defining eligibility was 15 ml/minute per
             1.73m(2) ≤eGFR&lt;60 ml/minute per 1.73m(2) or eGFR≥ 60 ml/minute per 1.73m(2) with
             &quot;nephrotic range&quot; proteinuria, which is defined as 24-hour urinary protein ≥3.5 g or
             urinary albumin creatinine ratio (ACR) ≥2 000 mg/g or corresponding values of urine
             dipstick test or urinary protein creatinine ratio (PCR).

          -  For non-glomerular nephrology and non-diabetic nephrology patients, 15 ml/minute per
             1.73m(2)≤eGFR&lt;60 ml/minute per 1.73m(2) is set for enrollment.

        Exclusion Criteria:

        Participants meeting even one of the listed items should be excluded.

          -  NYHA Class III or IV heart failure.

          -  Chronic kidney disease caused by systemic inflammatory illness or autoimmune disease,
             such as lupus erythematosus.

          -  Treated with immunosuppressive agents in the preceding 6 months to treat renal or
             immune disease.

          -  Self-reported or known diagnosis of HIV infection and/or AIDS.

          -  Isolated hematuria.

          -  Self-reported or known diagnosis of cirrhosis.

          -  Pregnant or breast-feeding women.

          -  Malignancy treated with chemotherapy within last 2 years.

          -  Renal or other transplantation.

          -  Hereditary kidney disease.

          -  Participation in interventional clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Minghui Zhao, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fang Wang, MD</last_name>
    <phone>011-86-10-83575535</phone>
    <email>wangfang@bjmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yunfei Bao, MS</last_name>
    <phone>011-86-10-83575535</phone>
    <email>ckdcohort@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunfei Bao, MS</last_name>
      <phone>011-86-10-83575535</phone>
      <email>ckdcohort@163.com</email>
    </contact>
    <investigator>
      <last_name>Luxia Zhang, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Gao B, Zhang L, Wang H, Zhao M. Chinese cohort study of chronic kidney disease: design and methods. Chin Med J (Engl). 2014;127(11):2180-5.</citation>
    <PMID>24902678</PMID>
  </reference>
  <results_reference>
    <citation>Zhou C, Wang F, Wang JW, Zhang LX, Zhao MH. Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease. Chin Med J (Engl). 2016 Oct 5;129(19):2275-80. doi: 10.4103/0366-6999.190678.</citation>
    <PMID>27647184</PMID>
  </results_reference>
  <results_reference>
    <citation>Yuan J, Zou XR, Han SP, Cheng H, Wang L, Wang JW, Zhang LX, Zhao MH, Wang XQ; C-STRIDE study group. Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol. 2017 Jan 14;18(1):23. doi: 10.1186/s12882-017-0441-9.</citation>
    <PMID>28088175</PMID>
  </results_reference>
  <results_reference>
    <citation>Peng Z, Wang J, Yuan Q, Xiao X, Xu H, Xie Y, Wang W, Huang L, Zhong Y, Ao X, Zhang L, Zhao M, Tao L, Zhou Q; C-STRIDE study group. Clinical features and CKD-related quality of life in patients with CKD G3a and CKD G3b in China: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). BMC Nephrol. 2017 Oct 13;18(1):311. doi: 10.1186/s12882-017-0725-0.</citation>
    <PMID>29029600</PMID>
  </results_reference>
  <results_reference>
    <citation>Yan Z, Wang Y, Li S, Wang J, Zhang L, Tan H, Li S, Yang L, Pei H, Zhang L, Wang Y, Duan J, Jiao S, Zhao M, Fu S; China National Survey of Chronic Kidney Disease Working Group. Hypertension Control in Adults With CKD in China: Baseline Results From the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). Am J Hypertens. 2018 Mar 10;31(4):486-494. doi: 10.1093/ajh/hpx222.</citation>
    <PMID>29304216</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang JJ, Yang L, Huang JW, Liu YJ, Wang JW, Zhang LX, Zhao MH, Liu ZS. Characteristics and comparison between diabetes mellitus and non-diabetes mellitus among chronic kidney disease patients: A cross-sectional study of the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). Oncotarget. 2017 Nov 10;8(63):106324-106332. doi: 10.18632/oncotarget.22368. eCollection 2017 Dec 5.</citation>
    <PMID>29290951</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2017</study_first_submitted>
  <study_first_submitted_qc>February 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2017</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Minghui Zhao</investigator_full_name>
    <investigator_title>Director of Renal Division, Department of Medicine</investigator_title>
  </responsible_party>
  <keyword>Cohort studies</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

